NRG-GI007

Closed to Accrual & Treatment

Return to Protocol Table

Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Cancer Who Are Not Candidates for Surgery

Principal Investigator

Geoffrey Ku

Status

Closed to Accrual & Treatment

Open to Accrual

June 29, 2020

Temporarily Closed to Accrual

April 21, 2023

Temporarily Closed to Accrual

June 27, 2023

Open to Accrual

August 7, 2023

Closed to Accrual

July 25, 2024

Closed to Accrual & Treatment

September 6, 2024


Disease Site

Gastrointestinal [GI] Esophageal

Phase

I

Developmental Therapeutics

Yes

Primary Objective

To determine if the addition of OBP-301
to chemoradiation with carboplatin/paclitaxel is safe.

Patient Population

Patients with pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ). Gastroesophageal junction tumors must be Siewert Type I/II. Patients  for whom non-operative management is a viable option in the opinion of a 
thoracic surgeon and/or multidisciplinary team and are candidates for  chemoradiation.

Target Accrual

21

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.